Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) shares are scheduled to reverse split on Tuesday, November 24th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, November 23rd.
Co-Diagnostics Stock Down 21.3%
Shares of CODX traded down $0.04 during midday trading on Friday, hitting $0.13. The company’s stock had a trading volume of 1,140,217 shares, compared to its average volume of 2,567,039. Co-Diagnostics has a one year low of $0.13 and a one year high of $13.54. The company’s fifty day simple moving average is $0.72 and its two-hundred day simple moving average is $2.03. The stock has a market capitalization of $1.36 million, a price-to-earnings ratio of -0.02 and a beta of 3.15.
Co-Diagnostics (NASDAQ:CODX – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.24. Co-Diagnostics had a negative net margin of 5,530.54% and a negative return on equity of 322.92%. The business had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.17 million.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on CODX. Weiss Ratings cut Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 11th. Wall Street Zen raised Co-Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Maxim Group upgraded Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $45.00.
Check Out Our Latest Research Report on CODX
Institutional Trading of Co-Diagnostics
A hedge fund recently bought a new stake in Co-Diagnostics stock. Susquehanna International Group LLP purchased a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 31,239 shares of the company’s stock, valued at approximately $97,000. Susquehanna International Group LLP owned about 0.85% of Co-Diagnostics as of its most recent filing with the SEC. 14.99% of the stock is owned by hedge funds and other institutional investors.
About Co-Diagnostics
Co-Diagnostics, Inc. is a molecular diagnostics company that develops technologies and tests for detecting infectious diseases. Based in Salt Lake City, Utah, the company’s work centers on its proprietary CoPrimer technology, used to design assays for polymerase chain reaction (PCR) testing. Its products include PCR-based diagnostic tests and related instruments, including the Co-Dx PCR platform. The company has developed tests for a range of infectious diseases, with product availability and regulatory status varying by market.
Featured Stories
- Five stocks we like better than Co-Diagnostics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
